For teams developing connected diagnostic equipment, imaging systems, or healthcare software, understanding the AI in medical diagnostics patent landscape is part of making informed technology and investment decisions. Patent activity spans many types of medical examinations and clinical applications, so a useful overview needs to look beyond a single algorithm or device category.
A 2019 landscape analysis by KnowMade examined more than 7,100 patent families relevant to artificial intelligence in medical diagnostics. Its coverage included patents published worldwide up to February 2019. The scope offers a useful illustration of how broad the field is—and why engineers, system integrators, and technical decision-makers may need structured ways to assess it.
Why map AI patents in medical diagnostics?
AI-related diagnostic innovation can involve data capture, signal or image analysis, and the interpretation of results. Patent documents may therefore relate to different parts of a diagnostic workflow, rather than to one stand-alone AI system. Mapping these documents by technical area and applicant can help organizations understand where intellectual property activity is concentrated and which questions merit further investigation.
For industrial automation professionals working with medical-device manufacturing or healthcare technology, this is relevant to product planning and collaboration. A patent landscape can provide context for evaluating technology directions, tracking competitors, and identifying possible partners. It is an information resource, not a substitute for engineering validation or legal advice.
A wide range of diagnostic technologies
The analysis included patent families associated with numerous examination modalities. These range from biochemical tests and blood-pressure measurement to cardiopulmonary sounds, electrocardiography, electroencephalography, and electromyography. Imaging applications included CT, MRI, ultrasound, X-rays, PET, optical coherence tomography, photoacoustic imaging, and minimally invasive imaging.
Other areas included facial and speech analysis, movement analysis, and elastography. This variety matters because the underlying inputs differ: an AI application may process images, physiological signals, measurements, or other forms of diagnostic data. When reviewing patent activity, teams should therefore consider the modality and the diagnostic use case together.
Clinical applications add another layer
The landscape also organized patents by clinical specialty. Areas covered included cardiology, diabetes, neurodegenerative disease and brain injury, ophthalmology, infectious disease, sleep disorders, and maternal and fetal monitoring. Oncology was examined broadly, with specific attention to breast, colorectal, liver, lung, prostate, and skin cancers.
This two-part structure—examination modality and clinical specialty—provides a practical way to frame an initial search. For example, a team could consider both the imaging method involved and the condition being assessed. That framing can make it easier to distinguish a general diagnostic technology from an application directed at a particular clinical area.
What a patent landscape can reveal
Patent counts alone do not explain the competitive position of a technology developer. The report’s analytical framework included publication timelines, filing countries, current legal status, applicant rankings, patent-family identification, and collaboration networks. It also examined portfolio strength, specialization, and potential blocking positions.
These dimensions answer different questions:
- Time and geography: Where and when have relevant patent applications been published or filed?
- Applicants and portfolios: Which organizations appear in the landscape, and how are their patent holdings distributed across technical areas?
- Legal status: What status is recorded for members of a patent family?
- Collaboration: Do patent records indicate joint development or other relationships between applicants?
- Key families: Which patent families have been identified for closer review?
The report highlighted profiles of 20 key players, including Siemens, Philips, General Electric, Fujifilm, Samsung Electronics, IBM, Medtronic, and Canon. Their inclusion demonstrates the cross-industry character of the field; it does not, by itself, establish a ranking or describe the current position of any organization.
Turning landscape information into a useful workflow
For technical and business teams, a landscape is most useful when linked to a defined decision. Before reviewing patents, clarify the technology and application boundaries. Then use relevant classifications—such as diagnostic modality, clinical specialty, applicant, geography, or legal status—to narrow the material to the question at hand.
A searchable database can support that process. The report described an Excel database containing fields such as publication number, priority date, title, abstract, assignee, technical segment, and legal status for patent-family members. These attributes help users filter records and trace a document back to its original publication.
However, patent landscape analysis is not a freedom-to-operate conclusion. The source explicitly distinguishes technical analysis from legal advice and does not provide an opinion on the validity of individual patents. Teams assessing product risk or planned commercialization should treat landscape findings as an input for appropriately scoped legal review.
Practical implications for technology decision-makers
AI in medical diagnostics is not one unified patent category. It spans multiple data types, examination methods, clinical specialties, and organizations. For automation and healthcare technology teams, that breadth makes careful scoping essential: broad searches can establish context, while focused searches can support specific development, partnership, or IP questions.
A structured patent landscape can help teams organize that complexity, compare activity across segments, and identify records for closer examination. Used with technical evaluation and legal counsel where needed, it can support more informed decisions about diagnostic innovation, collaboration, and intellectual property risk.